Lechleiter: Lilly Now in Position of Strength
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowIndianapolis-based Eli Lilly and Co. (NYSE: LLY) Chief Executive Officer John Lechleiter told attendees of a massive health care conference Tuesday that the company is entering its post-patent expiration period in a position of strength. During a speech at the JP Morgan Healthcare Conference in San Francisco, Lechleiter said the drugmaker could experience unprecedented oncology launch activity over the next five years.
Much of Lechleiter’s address focused on growing the company after the so-called "YZ" period. The patent cliff resulted in thousands of layoffs and billions of dollars in lost revenues. He outlined the drugmaker’s strategic objectives to grow revenue, expand margins, sustain flow of innovation and deploy capital to create revenue.
Lechleiter says, over the past 18 months, Lilly has filled out "the most complete portfolio of diabetes products in the industry." They include Jardiance, Glyxambi, Trulicity, Synjardy, Basaglar and the Humalog U200 KwikPen. In oncology, he says cancer treatment Cyramza has exceeded expectations and made a significant contribution to revenue.
The conference, often referred to as the "Super Bowl of Biotech," runs through Thursday. More than 10,000 biotech and pharmaceutical executives as well as venture capitalists and university representatives from around the globe are taking part.